|
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? |
Mar 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes: A Review of Therapeutic Progress Over the Past 10 Years |
Jun 2020 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress |
Jul 2023 |
Expert Review of Anticancer Therapies |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies |
Mar 2024 |
Expert Opinion on Biological Therapy |
Myelodysplastic Syndromes (MDS) |
|
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review |
Jul 2023 |
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
|
Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
May 2020 |
Experimental Hematology |
Myelodysplastic Syndromes (MDS) |
|
Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
Jun 2020 |
Experimental Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab |
Dec 2020 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry |
Jul 2020 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
Jul 2023 |
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
